AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 261 min read$TMO

CASPER MARC N sold $172K of TMO

CASPER MARC N (Chairman & CEO) sold 275 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $627.05 ($625.41–$628.74, $0.17M total) across 4 trades on 2026-08-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CASPER MARC N
Published Aug 26, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting limited immediate price impact.

02

Market read

Provides fresh insider transaction data for traders monitoring executive activity.

03

What to watch

Potential tax planning or portfolio rebalancing may drive the transaction, not company performance.

Relevance 3/10Novelty 4/10Timing: post‑market 2026-08-24

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

CEO Casper Marc N sold 275 shares for $172,438 via a 10b5-1 plan on 2026-08-24

Expected impact

Potential slight downward pressure, likely within normal volatility range

Evidence & confidence

The sale represents ~0.2% of the insider's post‑transaction holdings and is disclosed under a pre‑arranged plan, limiting immediate market reaction.

Market effects

Sector

Minimal impact on the life‑sciences equipment sector; insider sales are routine.

Regional

No significant regional effect; the filing is specific to Thermo Fisher.

Global

Limited global relevance; only relevant to investors tracking Thermo Fisher.

Counterpoint

What could challenge this read

The sale could be unrelated to company outlook, as 10b5‑1 plans are pre‑scheduled.

Key entities

  • Company
    Thermo Fisher Scientific Inc.

    US‑listed life‑sciences equipment and services provider (ticker TMO).

  • Individual
    Casper Marc N

    Chairman & CEO of Thermo Fisher Scientific.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TMO insider trading history →

Related articles

AUG 26
$DALMed

CNBC’s ‘Final Trades’: Delta Air, Target, Thermo Fisher Scientific - Delta Air Lines (NYSE:DAL)

CNBC's 'Final Trades' featured picks from analysts, including Delta Air Lines (DAL) for its strong Q2 earnings, Thermo Fisher Scientific (TMO) for its raised FY2026 guidance, and Target (TGT) for its better-than-expected Q2 results. Interactive Brokers (IBKR) was also mentioned for its new Latin America funding solution. DAL +1.4%, TMO -0.1%, TGT -3.8%, IBKR +5.5%.

benzinga.com2 min
AUG 18
$BIIBMed

Eyes on Asia: Tanabe Pharma, KYAN Technologies, Biogen

LEO Pharma agreed to acquire worldwide rights to Tanabe Pharma’s dersimelagon for up to $435m. The late-stage oral drug completed Phase III, with an FDA NDA filed June 2026. Thermo Fisher and KYAN Technologies will collaborate on precision oncology using patient-derived tumoroids. Biogen’s felzartamab won China NMPA approval for multiple myeloma. Expedition Therapeutics raised $115m Series B for EXPD-101 COPD Phase II.

bioxconomy.com5 min